Commitments and contingencies (Tables)

12 Months Ended

Dec. 31, 2020

Schedule of collaboration receivables and contract liabilities

	Balance at						Balance at
	December 31, 2019		Additions		Deductions		December 31, 2020
		(in thousands)
Related party collaboration receivable	$	18,496	$	35,952	$	(46,436)	$	8,012
Contract liabilities:
Deferred revenue	$	70,040	$		$	(26,351)	$	43,689

AbbVie Tau Collaboration Agreement

Schedule of allocation of transaction price

Performance Obligation	Amount
	(in thousands)
Research Services	$	34,482
First Development Option Material Right		34,518
Total	$	69,000

AbbVie Alpha Synuclein Collaboration Agreement

Schedule of allocation of transaction price

Performance Obligation	Amount
	(in thousands)
ASN Research Services	$	23,768
ASN First Development Option Material Right		41,232
Total	$	65,000

Neurocrine Collaboration Agreement

Schedule of allocation of variable consideration

Performance Obligation	Amount
	(in thousands)
Variable Consideration
VY-AADC Program	$	86,480
FA Program		87,991
Discovery Program 1		72,247
Discovery Program 2		69,515
Total	$	316,233

Schedule of allocation of fixed consideration

Performance Obligation	Amount
	(in thousands)
Fixed Consideration
VY-AADC Program	$	80,373
FA Program		6,005
Discovery Program 1		3,002
Discovery Program 2		3,002
Total	$	92,382